Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation
Esilida Sula Karreci, Siawosh K. Eskandari, Farokh Dotiwala, Sujit K. Routray, Ahmed T. Kurdi, Jean Pierre Assaker, Pavlo Luckyanchykov, Albana B. Mihali, Omar Maarouf, Thiago J. Borges, Abdullah Alkhudhayri, Kruti R. Patel, Amr Radwan, Irene Ghobrial, Martina McGrath, Anil Chandraker, Leonardo V. Riella, Wassim Elyaman, Reza Abdi, Judy Lieberman, Jamil Azzi
Esilida Sula Karreci, Siawosh K. Eskandari, Farokh Dotiwala, Sujit K. Routray, Ahmed T. Kurdi, Jean Pierre Assaker, Pavlo Luckyanchykov, Albana B. Mihali, Omar Maarouf, Thiago J. Borges, Abdullah Alkhudhayri, Kruti R. Patel, Amr Radwan, Irene Ghobrial, Martina McGrath, Anil Chandraker, Leonardo V. Riella, Wassim Elyaman, Reza Abdi, Judy Lieberman, Jamil Azzi
View: Text | PDF
Research Article Immunology Transplantation

Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation

  • Text
  • PDF
Abstract

Tregs hold great promise as a cellular therapy for multiple immunologically mediated diseases, given their ability to control immune responses. The success of such strategies depends on the expansion of healthy, suppressive Tregs ex vivo and in vivo following the transfer. In clinical studies, levels of transferred Tregs decline sharply in the blood within a few days of the transfer. Tregs have a high rate of apoptosis. Here, we describe a new mechanism of Treg self-inflicted damage. We show that granzymes A and -B (GrA and GrB), which are highly upregulated in human Tregs upon stimulation, leak out of cytotoxic granules to induce cleavage of cytoplasmic and nuclear substrates, precipitating apoptosis in target cells. GrA and GrB substrates were protected from cleavage by inhibiting granzyme activity in vitro. Additionally, we show — by using cytometry by time of flight (CYTOF) — an increase in GrB-expressing Tregs in the peripheral blood and renal allografts of transplant recipients undergoing rejection. These GrB-expressing Tregs showed an activated phenotype but were significantly more apoptotic than non–GrB expressing Tregs. This potentially novel finding improves our understanding of Treg survival and suggests that manipulating Gr expression or activity might be useful for designing more effective Treg therapies.

Authors

Esilida Sula Karreci, Siawosh K. Eskandari, Farokh Dotiwala, Sujit K. Routray, Ahmed T. Kurdi, Jean Pierre Assaker, Pavlo Luckyanchykov, Albana B. Mihali, Omar Maarouf, Thiago J. Borges, Abdullah Alkhudhayri, Kruti R. Patel, Amr Radwan, Irene Ghobrial, Martina McGrath, Anil Chandraker, Leonardo V. Riella, Wassim Elyaman, Reza Abdi, Judy Lieberman, Jamil Azzi

×

Figure 3

Quantitative differences between the expression of GrB+ Tregs among clinically verified rejection and nonrejection kidney transplant patients.

Options: View larger image (or click on image) Download as PowerPoint
Quantitative differences between the expression of GrB+ Tregs among clin...
(A) Identification of the starting population of CD127loCD25hi cells gated on CD4+ cells followed by the FoxP3+ gating. (B) Identification of the GrB+ and GrB– subsets, and (C) the expression of GrB among all Tregs in patients classified as nonrejectors (NR) and cellular rejectors (CR), respectively 23.55% ± 2.09% vs. 36.74% ± 4.77% (*P < 0.05). (D) Divergence between resting Tregs and memory and effector Tregs, gated on the parent population of (A) CD4+CD127loCD25hiFoxP3+ Tregs. (E and F) Identification of GrB subsets among the resting Tregs of NR and CR, 23.86% ± 1.93% vs. 38.67% ± 5.31% (**P < 0.01). (G) Divergence between memory and effector Tregs. (H and I) GrB subsets among the memory Tregs of NR and CR, 16.54% ± 2.46% vs. 31.52% ± 5.32% (*P < 0.05). (J and K) GrB subsets among the effector Tregs of NR and CR, 15.17% ± 1.89% vs. 24.39% ± 5.38%. (L) Identification of the FoxP3+CD45ROhi population gated on the parent population of (A) of CD4+CD127loCD25hi cells. (M) Divergence between Th1-like and Th17-like Tregs. (N and O) GrB subsets among the Th1-like Tregs of NR and CR, 23.12% ± 2.59% vs. 29.36% ± 6.65%. (P and Q) GrB subsets among the Th17-like Tregs of NR and CR, 24.41% ± 2.45% vs. 32.78% ± 7.35%. BCL-2, B cell lymphoma 2; CCR6, C-C chemokine receptor 6; CR, cellular rejector; CXCR3, C-X-C chemokine receptor 3; FoxP3, forkhead box P3; GrB, granzyme B; Ki-67, Kiel-67; NR, nonrejector; Th1, type 1 T helper cell; Th17, type 17 T helper cell.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts